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Correspondence Delayed Cardiac Tamponade After
Radiofrequency Catheter Ablation of Atrial Fibrillation
A Worldwide ReportTo the Editor: Catheter ablation is increasingly being offered for the
curative treatment of atrial fibrillation (AF). Generally, the proce-
dure is safe and effective (1), but the intense intraprocedural and
post-procedural anticoagulation regimen used, together with ex-
tensive catheter manipulation and application of radiofrequency
energy, may expose patients to an excessive risk for bleeding.
Although intraprocedural tamponade has been reported (1,2), little
is known about the incidence of delayed cardiac tamponade
(DCT). We investigated the incidence, modes of presentation, and
outcomes of DCT in a large population of patients undergoing this
procedure.
An anonymous volunteer reporting method was used to
identify cases that occurred between January 1995 and Decem-
ber 2006 at 102 centers contributing to our worldwide surveys
on the efficacy and safety of AF ablation (1,2). We defined
DCT as hypotension or cardiogenic shock requiring pericardial
drainage or causing death due to documented pericardial
effusion occurring at least 1 h post-procedurally but attributable
to the ablation procedure. Center experience, mapping and
ablation technique and catheter used, type of AF treated,
intraprocedural and post-procedural anticoagulation strategy,
and the occurrence of tamponade during the procedure were
compared at centers with and without cases of DCT to
determine potential risk factors. This survey was approved by
the institutional review board at Policlinico San Donato.
Patient and center characteristics were described by location
indexes if continuous or by frequencies and percentages if noncon-
tinuous. Contingency tables were created to calculate the influence
on the occurrence of DCT of center characteristics with regard to
experience, mapping and ablation strategy and catheter used, type
of AF, and anticoagulation strategy during and after the procedure.
Differences were calculated using chi-square tests of independence.
If any of the expected cell counts were lower than 5, the Fisher’s
exact test was applied using the algorithm proposed by Mehta and
Patel where the contingency table dimensions were greater than 2
 2. All the center-related variables that were associated (p 
0.10) with the presence of at least 1 DCT event were subsequently
tested in a multivariate model. Only the variable with the highest
statistical significance was tested in the multivariate model.
Forty-five cases of DCT after 27,921 procedures performed
in 21,478 patients were reported. Patients presented with DCT
a median of 12 days (range: 0.2 to 45 days) after the ablation
procedures. Four patients presented during their initial hospital
stays, whereas 41 patients were discharged after their ablation
procedures and presented subsequently to their primary care
physicians, emergency departments, or cardiologists with warn-
ing symptoms. Echocardiography proved diagnostic in all such
cases.Most patients presented with nonspecific symptoms, including
constant thoracic pain, neck or back pain, pain during breathing,
dyspnea, dizziness, nausea, fever, peripheral or global edema,
impending sense of doom or death, nausea, fever or general
malaise. One patient had cardiac arrest while swimming and was
found to have cardiac tamponade after resuscitation. Another
patient died suddenly and was found to have a large pericardial
effusion during the in-hospital resuscitation attempt. In 6 patients,
hypotension developed without warning. Two patients (5%) died,
1 from cardiac arrest 14 days after the procedure and 1 at 30 days
after a procedure complicated by cerebral thromboembolism that
had occurred 24 h after ablation. The mode of presentation of
hypotension varied, with 39 patients exhibiting gradual progres-
sion to cardiac tamponade and 6 patients experiencing severe
symptoms within minutes.
Therapy included pericardiocentesis in 36 patients and also
required pleural evacuation in another patient. A pericardial
surgical window was needed in 1 patient and open-chest surgery in
7 patients. In 36 patients, the hemorrhagic content of the pericar-
dial fluid was reported at visual inspection, whereas serous effusion
was the only finding in the remaining 9 patients.
When tested in the multivariate model (Table 1), the following
factors were independent predictors of at least 1 DCT event: large
volume of patients treated (odds ratio: 5.03), use of irrigation
catheter (odds ratio: 2.77), and treatment of paroxysmal AF only
(odds ratio: 3.97).
DCT occurred in 0.2% of patients in our series. Although
warning symptoms were present in most patients, hypotension and
shock were the presentation in 13% of patients. Warning symp-
toms were variable, including thoracic, neck and back pain, and
dyspnea and sometimes nonspecific symptoms such as dizziness,
nausea, fever, peripheral or global edema, impending sense of
doom or death, or general malaise. Eighty-four percent of patients
sought care from their primary care physicians, emergency depart-
ments, or general cardiologists rather than from the interventional
electrophysiologist. Evolution to cardiac tamponade mostly oc-
curred over hours or days, allowing access to medical aid, but
hemodynamic deterioration within minutes from the onset of
symptoms was observed in 13% of patients.
Retrospective series based on anonymous identification of cases
and retrospective medical record review have limitations. Although
anonymous identification of cases facilitates reporting of data on
poor outcomes, variability in prospective monitoring by many
physicians and of many procedures prevents accurate assessment of
the incidence of events, their presentation, and outcomes. These
limitations are further expanded by the late occurrence of DCT in
relationship to the date of AF ablation.
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fibrillation. Circulation 2005;111:1100–5.Letters to the EditorLate Gadolinium Enhancement
in Left Ventricular Dysfunction
After Trastuzumab
We read with great interest the report by Fallah-Rad et al. (1)
regarding echocardiography, biomarkers, and cardiac magnetic
resonance (CMR) in patients with trastuzumab-induced heart
failure. Cardiotoxicity after chemotherapy remains a clinical chal-
lenge. There is great interest in early detection of myocardial
damage before left ventricular (LV) function deteriorates, and
CMR is a good candidate to deliver this information. CMR isin various systemic and inflammatory diseases using specific
techniques (2). We would like to focus on the late gadolinium
enhancement (LGE) CMR findings.
The authors state in their discussion that “delayed enhancement
of the lateral wall of the LV within the mid-myocardium portion
[represents] a common feature in breast-cancer patients with
trastuzumab-induced cardiomyopathy.” This is an interesting find-
ing with a potentially high clinical impact. However, from our
point of view, more evidence is required to support this general
statement. Their current paper is the third publication by the
group regarding this subject with the same single CMR image
(once as a magnitude image, twice as a phase-sensitive reconstruc-
tion) depicting an intramural lateral lesion (1,3,4). This LGEeast 1rienci
n Coe
1.61
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1.38lesion in itself is unspecific and may or may not be related to
